Obligate intracellular pathogens such as Leishmania specifically target host phagocytes for survival and replication. Phosphoinositide 3-kinase γ (PI3Kγ), a member of the class I PI3Ks that is highly expressed by leukocytes, controls cell migration by initiating actin polymerization and cytoskeletal reorganization, which are processes also critical for phagocytosis. In this study, we demonstrate that class IB PI3K, PI3Kγ, plays a critical role in pathogenesis of chronic cutaneous leishmaniasis caused by L. mexicana. Using the isoform-selective PI3Kγ inhibitor, AS-605240 and PI3Kγ gene-deficient mice, we show that selective blockade or deficiency of PI3Kγ significantly enhances resistance against L. mexicana that is associated with a significant suppression of parasite entry into phagocytes and reduction in recruitment of host phagocytes as well as regulatory T cells to the site of infection. Furthermore, we demonstrate that AS-605240 is as effective as the standard antileishmanial drug sodium stibogluconate in treatment of cutaneous leishmaniasis caused by L. mexicana. These findings reveal a unique role for PI3Kγ in Leishmania invasion and establishment of chronic infection, and demonstrate that therapeutic targeting of host pathways involved in establishment of infection may be a viable strategy for treating infections caused by obligate intracellular pathogens such as Leishmania.
Obligate intracellular pathogens such as Leishmania specifically target host phagocytes for survival and replication. Phosphoinositide 3-kinase γ (PI3Kγ), a member of the class I PI3Ks that is highly expressed by leukocytes, controls cell migration by initiating actin polymerization and cytoskeletal reorganization, which are processes also critical for phagocytosis. In this study, we demonstrate that class IB PI3K, PI3Kγ, plays a critical role in pathogenesis of chronic cutaneous leishmaniasis caused by L. mexicana. Using the isoform-selective PI3Kγ inhibitor, AS-605240 and PI3Kγ gene-deficient mice, we show that selective blockade or deficiency of PI3Kγ significantly enhances resistance against L. mexicana that is associated with a significant suppression of parasite entry into phagocytes and reduction in recruitment of host phagocytes as well as regulatory T cells to the site of infection. Furthermore, we demonstrate that AS-605240 is as effective as the standard antileishmanial drug sodium stibogluconate in treatment of cutaneous leishmaniasis caused by L. mexicana. These findings reveal a unique role for PI3Kγ in Leishmania invasion and establishment of chronic infection, and demonstrate that therapeutic targeting of host pathways involved in establishment of infection may be a viable strategy for treating infections caused by obligate intracellular pathogens such as Leishmania. E ntry into host cells is essential for the survival and replication of obligate intracellular pathogens. Leishmania pathogens are obligate intracellular protozoan parasites that infect macrophages and neutrophils (1) . Although macrophages are the principle effector cells involved in eliminating Leishmania, they are also the target cells used by the parasites for their survival and replication within the host. Neutrophils have been suggested to act as a "Trojan horse" in establishing Leishmania infection (2) by internalizing parasites via mechanisms that fail to induce antileishmanial host responses (3, 4) . Furthermore, a recent study by Peters et al. (5) has shown that neutrophils harbor viable parasites during early stages of infection with Leishmania major and facilitate establishment of chronic infection by protecting parasites from extracellular destruction. To this effect, therapeutic targeting of pathways that mediate parasite entry into host cells could be a viable strategy for treating infections caused by Leishmania and possibly other obligate intracellular pathogens that target phagocytes.
The PI3Ks are a large family of enzymes that phosphorylate phosphoinositol-containing lipids (6) . Activation of PI3Ks results in the generation of phosphatidylinositol-3,4,5-triphosphate [PtdIns(3,4,5)P3], an important intermediate involved in intracellular signal transduction (6) . PI3Kγ is a class IB PI3K predominantly expressed by immune cells and consists of a catalytic subunit (p110γ) and a regulatory subunit (p101 or p84). PI3Kγ mediates signaling initiated primarily through G-protein coupled receptors (6) and plays a critical role in chemoattractant-induced cell migration by controlling actin cytoskeletal rearrangement (6-9).
Activation of PI3Kγ results in the generation of PtdIns(3,4,5)P 3 and the activation of Akt (6) . PtdIns(3,4,5)P 3 cooperates with Gβγ subunits to initiate actin polymerization and subsequent Factin accumulation induced by PI3Kδ (6) . Neutrophils from PI3Kγ −/− mice display impaired activation of Rac and reduced Factin accumulation at the leading edge, which correlate with their reduced ability to migrate in response to chemotactic stimuli (10, 11) . Studies using PI3K inhibitors, such as wortmannin or LY294002, show that type I PI3Ks are involved in phagocytosis (12) (13) (14) (15) and mediate the entry of parasites, such as Trypanosoma cruzi, into host cells (16) (17) (18) . The precise role of each isoform, however, remains unclear. A study by Gagnon et al. (19) has suggested that endoplasmic reticulum (ER)-mediated phagocytosis is a possible mechanism of entry of Leishmania into macrophages and that inhibition of PI3K activity using 3-methyladenine and wortmannin markedly suppresses ER-mediated uptake of latex beads into macrophages in vitro. Taken together, these findings led us to hypothesize that by initiating actin polymerization and cytoskeletal rearrangement, PI3Kγ may contribute to establishment of chronic Leishmania infection by recruiting macrophages and/or neutrophils to the site of infection and by facilitating uptake of parasites into these cells.
In this study, we examined the role of PI3Kγ in the development of chronic cutaneous leishmaniasis (CL) caused by Leishmania mexicana and determined whether this enzyme might be a potential therapeutic target for the treatment of this disease. Our results demonstrate that PI3Kγ-mediated pathways play a critical role in establishment of chronic L. mexicana infection by mediating the recruitment of phagocytes and regulatory T cells (Tregs) to the site of infection and by facilitating entry of parasites into phagocytes. Most importantly, we provide "proof-of-concept" that targeting the host pathway contributing to establishment of chronic infection could be a therapeutically viable option for treating infections caused by obligate intracellular pathogens like Leishmania.
Author contributions: C.W. and A.R.S. designed research; H.E.C., J.B., P.R., S.O., N.Z., T.L.K., S.V., and C.L.-D. performed research; A.S., B.L., T.R., M.D.W., C.W., D.R., C.R., and S.S. contributed new reagents/analytic tools; H.E.C., J.B., C.L.-D., C.R., S.S., and A.R.S. analyzed data; and A.R.S. wrote the paper. (20) . We found that AS-605240 significantly reduced the uptake of L. mexicana promastigotes into mouse bone marrow-derived macrophages (BMDMs) (Fig. 1A) and neutrophils (PMNs) (Fig. 1B) , as well as human monocyte-derived macrophages (HMDMs) (Fig. 1C) . AS-605240 was also effective in inhibiting uptake of L. mexicana amastigotes into mouse BMDMs (Fig. 1D ) The inhibitory effect of AS-605240 on parasite entry into BMDMs and neutrophils was further confirmed using flow cytometry (Fig. 1E) . The inhibitory effect of AS-605240 on phagocytosis by macrophages was not specific for the uptake of Leishmania parasites alone, because C57BL/6 WT primary BMDMs (Fig. S1A) , as well as macrophage cell line (ANA-1) (Fig. S1B) , treated with AS-605240 and incubated with collagen-coated fluorobeads showed nearly a 50% reduction in the number of intracellular beads compared with saline-treated controls. Similarly, using macrophage cell lines generated from bone marrow of neonatal C57BL/6 WT and PI3Kγ −/− mice (Fig. S1C) , as well as primary BMDMs from C57BL/6 WT and PI3Kγ −/− mice ( Fig. S1 D and E), we further confirmed that PI3Kγ is involved in mediating parasite entry into macrophages in vitro, because L. mexicana-infected macrophages derived from PI3Kγ −/− mice contained significantly fewer intracellular parasites compared with PI3Kγ +/+ WT-derived macrophages.
AS-605240 Significantly Reduces Entry of L. mexicana into Neutrophils
and Macrophages in Vivo. To investigate the effect of PI3Kγ blockade on parasite uptake in vivo, dorsal s.c. air pouches were created on WT C57BL/6 mice as described previously (21, 22) . These pouches were injected with LPS or thioglycollate to recruit neutrophils and macrophages, respectively, followed by subsequent injection of fluorescent L. mexicana promastigotes in the presence of AS-605240 or saline vehicle. C57BL/6 mice injected with AS-605240 contained fewer parasitized macrophages and neutrophils in their dorsal pouches compared with saline controls (Fig. 1F ). Similar decreases in parasitized macrophages were also observed in macrophages infected with axenic L. mexicana amastigotes ( Fig. S2) , as well as IgG-opsonized axenic amastigotes, with the latter representing the physiologically relevant form of amastigotes present in the mammalian host (Fig. 1G ). The effect of AS-605240 on amastigote uptake by neutrophils was not investigated, because neutrophils are known to interact primarily with Leishmania promastigotes in vivo only during the early phase of infection after sand fly bite (5).
The phagocytic receptors complement receptor (CR)3 and Fc gamma receptor (FcγR) have been implicated as the major receptors used by Leishmania parasites to gain entry into host macrophages. We therefore determined whether the reduced uptake of Leishmania parasites into phagocytes observed both in vitro and in vivo could be attributed to decreased expression of phagocytic receptors (CD11b, CD18, and CD16/32) on AS-605240-treated cells. We found that AS-605240 treatment did not alter the level of these receptors expressed by macrophages in vitro (Fig. S3) . Taken together, these data demonstrate that suppression of parasite phagocytosis into AS-605240-treated macrophages was not attributable to reduction in levels of CR3 and FcγR.
Treatment with AS-605240 Significantly Reduces Lesion Growth and
Parasite Loads in L. mexicana-Infected C57BL/6 Mice. Because AS-605240 treatment displayed no cytotoxic effects against host cells in vitro (Fig. S4 ) and effectively reduced entry of Leishmania into macrophages and neutrophils both in vitro and in vivo, we investigated whether AS-605240 could be used as a therapeutic agent to treat CL. L. mexicana-infected mice treated with AS-605240 failed to develop lesions, or developed significantly smaller lesions containing significantly fewer parasites, compared with saline-treated controls ( Fig. 2 A and B) .
The ear lesions from AS-605240-treated mice contained fewer inflammatory cells and parasitized macrophages compared with the lesions of control mice, which showed ulceration and necrosis, as well as an increased inflammatory infiltrate composed of heavily parasitized macrophages, neutrophils, and eosinophils (Figs. S5 and S6). L. mexicana-infected mice treated with AS-605240 contained significantly fewer macrophages (1.09 ± 0.2 × 10 3 F4/80 + cells) within their lesions compared with control mice treated only with saline (5.83 ± 0.11 × 10 3 F4/80 + cells; P < 0.05). This is perhaps not surprising, because PI3Kγ is well known for mediating intracellular signaling involved in initiating actin polymerization and cytoskeletal reorganization in response to inflammatory stimuli. This impairment in recruitment of inflammatory cells to the site of infection likely contributes, in part, to the protective phenotype observed in mice treated with AS-605240 to inhibit PI3Kγ activity in vivo. These findings are promising and suggest that therapeutic use of PI3Kγ isoform-selective kinase inhibitors may be a viable strategy for treating Leishmania infection and possibly other intracellular pathogens of phagocytes. (1, (23) (24) (25) . We therefore examined the effect of AS-605240 treatment on Th1/Th2 cytokine responses. Eight weeks postinfection, lymph node cells from AS-605240-treated and control mice were stimulated with L. mexicana antigen (LmAg) in vitro, and IFN-γ, IL-12p70, IL-10, and IL-4 levels were determined by ELISA. LmAg-stimulated lymph node cells from AS-605240-treated mice produced less Th2-associated IL-4 and IL-10 than saline controls; however, the levels of Th1-associated IL-12 and IFN-γ were comparable between both groups (Fig. 2 C-F) . We believe that suppression of Th2 cytokine production is an indirect effect of AS-605240 on T cells, because AS-605240-treated naive T cells from C57BL/6 WT mice, as well as T cells from PI3Kγ −/− mice, did not show reduced production of Th2 cytokines IL-4 and IL-10 after in vitro stimulation with anti-CD3/anti-CD28 antibodies (Fig. S7) . Taken together, these findings demonstrate that AS-605240 treatment is associated with a reduction in Th2 cytokine production in L. mexicana-infected mice, which could contribute to control of parasite replication observed in these mice.
A previous study by Belkaid et al. (26) has shown that CD4 + CD25 + Tregs play a critical role in pathogenesis of chronic L. major infection by suppressing activity of CD4 + effector cells in an IL-10-dependent and -independent manner. Recently, Liu et al. (27) reported that PI3Kδ, a class IA PI3K that regulates actin polymerization together with PI3Kγ, controls susceptibility to L. major by regulating expansion and tissue homing of Tregs. We therefore examined the effect of PI3Kγ blockade on recruitment and IL-10 production by CD4 + FoxP3 + Tregs in L. mexicanainfected C57BL/6 FoxP3-EGFP knock-in mice (Fig. 3) . Cell filtrates from infected ears were serially diluted across 96-well plates in duplicate and incubated at 26°C for 7-14 d, when the greatest dilution yielding viable parasites was recorded for each ear. Data are presented as the mean log parasite dilution ± SE from three independent experiments (n = 15 mice per group). *P < 0.05 as determined by a Mann-Whitney U prime test. Quantification of Th1/Th2 cytokine production was done by draining lymph node cells from infected mice as determined by ELISA. Cells were restimulated ex vivo with LmAg (20 μg/mL) for 72 h and analyzed for production of IL-4 (C), IL-10 (D), IL-12 (E), and IFN-γ (F). Data are expressed as the mean cytokine level (pg/mL) ± SE from three independent experiments (n = 9-15 mice per group) with similar results. *P < 0.05 as determined by an unpaired Student's t test. AS-605240 treatment significantly reduced recruitment of CD4 + FoxP3 + Tregs to the infected lesions but had no effect on Treg populations within the draining lymph nodes of these mice ( Fig. 3 A and B) . Furthermore, AS-605240 had no significant effect on IL-10 production by CD4 + FoxP3 + Treg cells in vitro ( Fig. 3 C  and D) . Naive C57BL/6 WT and PI3Kγ −/− mice were found to contain comparable proportions of CD4 + FoxP3 + Tregs within their lymph nodes and spleens, suggesting that class IB PI3Kγ is not involved in the generation of these cells in vivo (Fig. 3 E and  F) . Collectively, these data suggest that PI3Kγ does not regulate development, expansion, or IL-10 production by Tregs but, instead, may contribute to the pathogenesis of L. mexicana infection by mediating trafficking of these cells to the site of infection. This is perhaps not surprising in light of a recent study by Anderson et al. (28) reporting that CD4 + CD25 − Foxp3 − Th1 cells are the source of IL-10-mediated immune suppression in chronic CL.
Treatment with AS-605240 Is as Effective as Sodium Stibogluconate in
Reducing Parasite Growth in L. mexicana-Infected C57BL/6 Mice.
Because AS-605240 treatment was found to limit disease progression and reduce disease-associated pathology in mice, we compared the therapeutic efficacy of AS-605240 with that of the standard antileishmanial drug sodium stibogluconate (SSG).
Over a 7-wk period, L. mexicana-infected C57BL/6 mice were monitored for the development of visible ulcerating cutaneous lesions at the site of infection. Beginning at week 7 postinfection, infected mice received twice-daily treatment with AS-605240 (15 mg/kg), SSG (20 mg/kg), or saline vehicle for a period of 2 wk. On cessation of treatment (9 wk postinfection), infected mice were euthanized and parasite burdens were determined by limiting dilution analysis. As was expected 9 wk postinfection, salinetreated control mice contained significant numbers of parasites within their lesions (Fig. 4A) . In contrast, the infected ears of mice treated with AS-605240 or SSG contained significantly fewer parasites (nearly 2 logs less) than saline-treated controls (Fig. 4A) . Most importantly, however, both AS-605240-treated and SSG-treated mice displayed comparable reductions in ear parasite burdens (Fig. 4A) .
Histopathological analysis of ear lesions obtained from L. mexicana-infected C57BL/6 control mice revealed significant tissue inflammation and extensive inflammatory cell infiltration composed of heavily parasitized macrophages, neutrophils, and eosinophils (Fig. 4B) . In contrast, AS-605240-treated mice exhibited a substantial reduction in tissue inflammation and harbored significantly fewer parasites within the infected lesions (Fig. 4C) . The diminished disease-associated pathological findings observed in AS-605240-treated mice were comparable to those observed in mice receiving standard therapy with SSG (Fig. 4D) . These results show that AS-605240 is as effective as SSG in reducing disease progression and limiting parasite growth in mice when administered late after disease onset. Finally, we determined the efficacy of AS-605240 to limit disease progression when administered in conjunction with SSG. L. mexicana-infected mice receiving a combination therapy of AS-605240 and SSG developed smaller lesions and harbored fewer parasites within their lesions than mice treated with either AS-605240 or SSG alone (Fig. 4A) . As might be expected, histopathological analysis of mice receiving a combination therapy of AS-605240 and SSG demonstrated a similar reduction in inflammatory cell infiltration and tissue inflammation at the site of infection compared with controls (Fig. 4E) . Collectively, these findings suggest that a combination therapy using standard chemotherapy, in conjunction with PI3Kγ isoform-selective kinase inhibitors, could be more effective in the treatment of CL.
L. mexicana Parasites Fail to Establish Efficient Infection in p110γ
Gene-Deficient C57BL/6 Mice. To confirm the role of PI3Kγ in the pathogenesis of L. mexicana infection further, C57BL/6 mice lacking the p110γ catalytic subunit of the enzyme (PI3Kγ −/− mice) were infected by injecting 10 4 L. mexicana promastigotes into the ear dermis. Infection was monitored as described previously.
L. mexicana-infected PI3Kγ
−/− mice developed significantly smaller lesions than their WT counterparts (Fig. 5A ) and harbored significantly lower parasite burdens (Fig. 5B) . Lesion sizes and parasite burdens in PI3Kγ −/− mice were comparable to those observed in AS-605240-treated WT mice (Fig. 2 A and B) . PI3Kγ −/− mice also recruited fewer cells to the site of infection and showed a 50-60% reduction in immune cells, including macrophages, neutrophils, and T cells. Furthermore, LmAg-stimulated lymph node cells from these mice also produced significantly less IL-10 compared with WT controls (1,416 ± 271 pg/mL and 416 ± 112 pg/mL in WT and PI3Kγ −/− mice, respectively; P < 0.05). No significant difference was observed in IL-4 production between the groups, although levels of IL-4 were slightly lower in culture supernatants from PI3Kγ −/− mice (125 ± 15 pg/mL and 82 ±17 pg/mL in WT and PI3Kγ
−/− mice, respectively). These findings validate the role of PI3Kγ in the pathogenesis of cutaneous L. mexicana infection.
Discussion
Our study reveals a unique role for PI3Kγ in mediating host cell invasion by Leishmania and provides "proof-of-principle" that targeting the intracellular kinase activity of PI3Kγ could be a therapeutically viable option for treating infections caused by obligate intracellular pathogens and for limiting infection-induced pathological changes by inhibiting the recruitment of disease-exacerbating immune cells to the site of infection.
Conventional approaches for treating infections caused by obligate intracellular pathogens such as Leishmania and Mycobacteria have focused on drugs that target unique molecules or pathways in the pathogen. Although such strategies have been effective, the emergence of drug-resistant pathogens to conventional therapeutics is becoming a significant problem in the treatment of leishmaniasis, as well as many other pathogens such as Mycobacterium tuberculosis and Salmonella (29, 30) . Furthermore, the standard drugs that are used to treat leishmaniasis, such as SSG, are toxic and have poor patient compliance because of long treatment times ranging from 3 to 5 wk and the requirement for parenteral administration. Therefore, treating infectious diseases by targeting host pathways that are critical for pathogen invasion and survival has recently been considered as a viable option for developing new therapeutic agents against infectious diseases (31) . Some studies have reported that targeting host molecules inhibits intracellular growth of bacteria and parasites such as Plasmodium in the host cell in vitro (32) . However, the therapeutic efficacy of this approach in vivo has not been tested in the treatment of bacterial or parasitic diseases in vivo. Our findings in the present study demonstrate that in vivo targeting of host pathways essential for pathogen invasion could be effective in limiting infection and show that PI3Kγ signaling could be a potential drug target for the treatment of intracellular pathogens that require host hematopoietic cells for survival and replication.
A recent study by Liu et al. (27) has found that PI3Kδ also controls susceptibility to CL caused by L. major by regulating the expansion and tissue homing of the Tregs that are involved in pathogenesis (27) . In the present study, we found that although PI3Kγ blockade/deficiency significantly reduced recruitment of Tregs to the lesion, it had no effect on development, expansion, or IL-10 production from these cells. Interestingly, Liu et al. (27) found that PI3Kδ was not involved in mediating uptake of parasites into host phagocytes. This is perhaps not surprising, because both PI3Kγ and PI3Kδ, which are primarily expressed in hematopoietic cells and endothelial cells, have been reported to have related yet nonredundant roles. Taken together, these findings indicate that both PI3Kγ and PI3Kδ mediate susceptibility to CL through multiple mechanisms, and could therefore be therapeutic targets for treatment of this infection. Dual PI3Kδ/PI3Kγ-deficient mice have been shown to have defects in T-cell development and thymocyte survival (33, 34) ; therefore, one concern for targeting of PI3Kγ and PI3Kδ, or both, in host cells could be that blockade of these enzymes could be toxic and lead to enhanced susceptibility of the host to other infections. Therefore, PI3Kδ/PI3Kγ inhibitors may need to be used in combination with conventional antimicrobial agents. Nonetheless, in the present study, we found that Leishmania antigen-stimulated lymph node cells from both control and AS-605240-treated mice produced comparable levels of IFN-γ, indicating that PI3Kγ blockade has no effect on induction of Th1-like responses. Furthermore, several PI3Kδ and PI3Kγ inhibitors, as well as dual-specificity PI3Kδ/PI3Kγ inhibitors, are currently in development for clinical use as antiinflammatory and antiproliferative agents (35) , and have been found to be safe in phase I clinical trials.
In conclusion, our study shows that PI3Kγ mediates susceptibility CL caused by L. mexicana by mediating recruitment of Tregs and phagocytes into the lesions and by facilitating uptake of parasites in macrophages and neutrophils. In addition, our findings show that blockade of PI3Kγ activity in vivo using an isoform-selective small-molecule inhibitor is therapeutically as effective as the standard antileishmanial drug SSG in limiting disease progression and parasite growth. These findings suggest that dualspecificity PI3Kδ/PI3Kγ inhibitors or inhibitors with similar activity, such as AS-605240, could be therapeutic agents to treat infections caused by intracellular pathogens.
Materials and Methods
In Vitro Parasite Uptake Assay by Fluorescence Microscopy. BMDMs, PMNs, or HMDMs (3.5 × 10 5 cells/mL) were cultured on 1.5-mm glass coverslips at 37°C/ 5% (vol/vol) CO 2 and allowed to adhere overnight. Adherent cells were treated with AS-605240 (1.25 μM) or 1× sterile saline (vehicle) 30 min before infection. Infected cells were incubated at 33°C/5% (vol/vol) CO 2 . Cells were washed, fixed in 3% paraformaldehyde, stained, and mounted on glass coverslips (see above) for imaging. All uptake assays were performed at a ratio of 7:1 parasites/cells.
In Vivo Parasite Uptake Assay. Dorsal s.c. air pouches were created on the shaven backs of C57BL/6 mice by injection with 3 mL of sterile air. These pouches subsequently received injections with either thioglycollate (2 mL) or LPS (20 μg/mL) to recruit macrophages or neutrophils, respectively. Ninety-six hours (for macrophage studies) or 3 h (for neutrophil studies) later, these pouches were infected with 2-5 × ACKNOWLEDGMENTS. Research in the Satoskar laboratory is funded by grants from the National Institutes of Health.
